There are 3 versions of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (3)

Short Titles

Short Titles - House of Representatives

Short Titles as Passed House

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

Short Titles as Introduced

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another eligible illness, and for other purposes.


Actions Overview (3)

Date
03/21/2018Passed/agreed to in House: On passage Passed by recorded vote: 267 - 149 (Roll no. 121).(text: CR H1738-1739)
03/13/2018Failed of passage/not agreed to in House: On motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
03/13/2018Introduced in House

All Actions (26)

Date Chamber
04/09/2018SenateRead the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 367.
03/23/2018SenateRead the first time. Placed on Senate Legislative Calendar under Read the First Time.
03/22/2018SenateReceived in the Senate.
03/21/2018-9:54pmHouseMotion to reconsider laid on the table Agreed to without objection.
03/21/2018-9:54pmHouseOn passage Passed by recorded vote: 267 - 149 (Roll no. 121). (text: CR H1738-1739)
03/21/2018-9:44pmHouseOn motion to recommit with instructions Failed by the Yeas and Nays: 182 - 233 (Roll no. 120).
03/21/2018-9:16pmHouseConsidered as unfinished business. (consideration: CR H1748-1750)
03/21/2018-2:08pmHousePOSTPONED PROCEEDINGS - At the conclusion of debate on the Pallone motion to recommit with instructions, the Chair put the question on the motion and by voice vote announced that the ayes had prevailed. Mr. Pallone demanded the yeas and nays, and the Chair postponed further proceedings on the motion to recommit until later in the legislative day.
03/21/2018-2:07pmHouseThe previous question on the motion to recommit with instructions was ordered without objection.
03/21/2018-2:01pmHouseDEBATE - The House proceeded with 10 minutes of debate on the Pallone motion to recommit with instructions. The instructions contained in the motion seek to report the same back to the House forthwith with an amendment to require the Food and Drug Administration (FDA) to issue guidance describing how the agency will use expanded access outcomes when considering and evaluating investigational products for full approval. Additionally, the motion seeks to provide liability protection to manufacturers, physicians, and hospitals offering a product under expanded access, as long as the entity is in compliance with current federal law, and it also increases transparency in the FDAs expanded access program.
03/21/2018-2:00pmHouseMr. Pallone moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1746-1747)
03/21/2018-1:59pmHouseThe previous question was ordered pursuant to the rule.
03/21/2018-1:02pmHouseDEBATE - The House proceeded with one hour of debate on H.R. 5247.
03/21/2018-1:01pmHouseThe resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
03/21/2018-1:01pmHouseConsidered under the provisions of rule H. Res. 787. (consideration: CR H1738-1748)
03/20/2018-2:19pmHouseRule H. Res. 787 passed House.
03/19/2018-7:08pmHouseRules Committee Resolution H. Res. 787 Reported to House. The resolution provides for one hour of debate on each bill. The resolution makes in order only the further amendment to H.R. 4566 printed in the report. No further amendments on either bill are made in order. Section 3 of the resolution makes it in order to consider any resolution reported from the Rules Committee on the day it is reported through the legislative day of March 23, 2018. Section 4 grants suspension authority on the legislative days of March 22, 2018 and March 23, 2018. Section 5 of the resolution amends section 3(a) of H. Res. 5.
03/16/2018HouseReferred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
03/13/2018-6:56pmHouseOn motion to suspend the rules and pass the bill Failed by the Yeas and Nays: (2/3 required): 259 - 140 (Roll no. 102).
03/13/2018-6:29pmHouseConsidered as unfinished business. (consideration: CR H1528-1529)
03/13/2018-6:25pmHouseAt the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
03/13/2018-5:40pmHouseDEBATE - The House proceeded with forty minutes of debate on H.R. 5247.
03/13/2018-5:40pmHouseConsidered under suspension of the rules. (consideration: CR H1521-1527; text of measure as introduced: CR H1521-1522)
03/13/2018-5:40pmHouseMr. Walden moved to suspend the rules and pass the bill.
03/13/2018HouseReferred to the House Committee on Energy and Commerce.
03/13/2018HouseIntroduced in House

Cosponsors (44)

* = Original cosponsor
CosponsorDate Cosponsored
Rep. Biggs, Andy [R-AZ-5]* 03/13/2018
Rep. Griffith, H. Morgan [R-VA-9]* 03/13/2018
Rep. Barr, Andy [R-KY-6]* 03/13/2018
Rep. Barton, Joe [R-TX-6]* 03/13/2018
Rep. Blackburn, Marsha [R-TN-7]* 03/13/2018
Rep. Buchanan, Vern [R-FL-16]* 03/13/2018
Rep. Carter, Earl L. "Buddy" [R-GA-1]* 03/13/2018
Rep. Burgess, Michael C. [R-TX-26]* 03/13/2018
Rep. Comstock, Barbara [R-VA-10]* 03/13/2018
Rep. Cramer, Kevin [R-ND-At Large]* 03/13/2018
Rep. Culberson, John Abney [R-TX-7]* 03/13/2018
Rep. Black, Diane [R-TN-6]* 03/13/2018
Rep. Dunn, Neal P. [R-FL-2]* 03/13/2018
Rep. Faso, John J. [R-NY-19]* 03/13/2018
Rep. Hill, J. French [R-AR-2]* 03/13/2018
Rep. Gallagher, Mike [R-WI-8]* 03/13/2018
Rep. Handel, Karen C. [R-GA-6]* 03/13/2018
Rep. Hartzler, Vicky [R-MO-4]* 03/13/2018
Rep. Issa, Darrell E. [R-CA-49]* 03/13/2018
Rep. Lewis, Jason [R-MN-2]* 03/13/2018
Rep. Buck, Ken [R-CO-4]* 03/13/2018
Rep. Lamborn, Doug [R-CO-5]* 03/13/2018
Rep. Marshall, Roger W. [R-KS-1]* 03/13/2018
Rep. Meadows, Mark [R-NC-11]* 03/13/2018
Rep. Messer, Luke [R-IN-6]* 03/13/2018
Rep. Brooks, Mo [R-AL-5]* 03/13/2018
Rep. Gosar, Paul A. [R-AZ-4]* 03/13/2018
Rep. Rothfus, Keith J. [R-PA-12]* 03/13/2018
Rep. Schweikert, David [R-AZ-6]* 03/13/2018
Rep. Sinema, Kyrsten [D-AZ-9]* 03/13/2018
Rep. King, Steve [R-IA-4]* 03/13/2018
Rep. Yoho, Ted S. [R-FL-3]* 03/13/2018
Rep. Weber, Randy K., Sr. [R-TX-14]* 03/13/2018
Rep. Collins, Chris [R-NY-27]* 03/13/2018
Rep. Yoder, Kevin [R-KS-3]* 03/13/2018
Rep. Harper, Gregg [R-MS-3]* 03/13/2018
Rep. Lance, Leonard [R-NJ-7]* 03/13/2018
Rep. Allen, Rick W. [R-GA-12]* 03/13/2018
Rep. Duncan, Jeff [R-SC-3]* 03/13/2018
Rep. Herrera Beutler, Jaime [R-WA-3]* 03/13/2018
Rep. Calvert, Ken [R-CA-42] 03/14/2018
Rep. Huizenga, Bill [R-MI-2] 03/14/2018
Rep. Rokita, Todd [R-IN-4] 03/19/2018
Rep. Newhouse, Dan [R-WA-4] 03/19/2018

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Energy and Commerce03/13/2018 Referred to
House Energy and Commerce Subcommittee on Health03/16/2018 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Latest Summary (1)

There is one summary for H.R.5247. View summaries

Shown Here:
Introduced in House (03/13/2018)

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to exempt, from specified requirements and restrictions under that Act and other laws, the provision of certain unapproved, investigational drugs to a terminally ill patient who has exhausted approved treatment options and is unable to participate in a clinical trial involving the drugs. The manufacturer or sponsor of an eligible investigational drug must publish annual summaries on any use of the drug in accordance with these provisions.

The bill limits the liability of a sponsor, manufacturer, licensed physician, clinical investigator, or hospital that provides, or declines to provide, an eligible investigational drug to an eligible patient in accordance with the bill.